Global biopharmaceutical company AstraZeneca has announced plans to invest $15 billion in China by 2030, aiming to expand research, development, and manufacturing of new medicines.
The investment is designed to strengthen the company’s ability to discover, develop, and produce innovative treatments, while also supporting collaboration between the Chinese and UK life sciences ecosystems.
Why China?
Over the past decade, China has become an increasingly important hub for biomedical research, clinical trials, and advanced manufacturing. AstraZeneca already operates major R&D centers in Beijing and Shanghai, working with more than 500 clinical hospitals on global studies.
By expanding its presence, the company hopes to accelerate the development of next-generation therapies, including:
• cell therapies – treatments that use modified living cells to fight disease
• radioconjugates – medicines that deliver targeted radiation directly to cancer cells
These technologies are seen as some of the most promising approaches for treating cancer, blood disorders, and autoimmune diseases.
Expanding research and manufacturing
As per the press release, the investment will support activities across the entire drug development pipeline, from early discovery and clinical trials to large-scale manufacturing.
AstraZeneca plans to expand existing facilities in Wuxi, Taizhou, Qingdao, and Beijing, while also developing new sites in the coming years. The expansion is expected to grow the company’s workforce in China to more than 20,000 employees and create thousands of additional jobs across the healthcare sector.
The company will also deepen collaborations with Chinese biotech companies and global research institutions. Partnerships already include organizations such as AbelZeta, Harbour BioMed, and Jacobio Pharma.
Strengthening global research partnerships
The initiative is also intended to strengthen ties between the UK and Chinese life sciences sectors. AstraZeneca is working with several universities and institutions (including University of Cambridge, University of Oxford, University of Glasgow, and King’s College London) to expand research collaborations between the two countries.
Ultimately, the investment is part of AstraZeneca’s broader strategy to accelerate the development of innovative medicines and improve access to treatments for patients worldwide.
